Ocular Therapeutix Inc. [OCUL] Downgraded to Neutral at H.C. Wainwright

TDOC Stock
TDOC Stock

H.C. Wainwright took its Ocular Therapeutix Inc. [OCUL]‎ rating to the equivalent of Neutral from Buy, in a research note dated December 28, 2020. Some new analysts also started their coverage, with ‎Berenberg’s analysts assigning the shares to “a Buy” rating in a research note to investors issued in mid ‎December. Meanwhile, Raymond James had maintained its rating on OCUL to the earlier “Strong buy” ‎rating, in a research note produced for clients November 13, 2020. In addition, there was no change ‎from H.C. Wainwright on August 10, 2020. The rater maintained OCUL to “a Buy” but assigned new ‎target price of $13.

Get the hottest stocks to trade every day before the ‎market opens 100% free. Click here now. 

Is Ocular Therapeutix Inc. [NASDAQ:OCUL] a Good Buy Right Now?

It should be noted that ‎OCUL technical indicators for short, intermediate as well as long term progress have placed an overall ‎average of 100% as Buy. The average signal changed from 100% Buy in the last week and compares ‎with 100% Buy in the past month. Data from Ocular Therapeutix Inc.’s Trend Spotter indicated that the ‎signals were Weakening. The stock current average is 1.4 million shares in the past 20 days and the ‎short term average signal indicates a 100% Buy. In the last 50 days, the average trading volume was ‎‎1.26 million shares while the medium term average advocated for 100% Buy. The average long-term ‎signal stands at 100% Buy and the 100-day average volume stands at 1.18 million shares.‎‎

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


OCUL Price Performance

On Wall Street, Ocular Therapeutix Inc. [NASDAQ:OCUL] finished ‎Thursday’s session up 0.45% at $22.08. The stock went up to $22.54 at the same session while its ‎lowest single day price was $21.63. In the last five days, it saw a rise of about 2.60%, Ocular Therapeutix ‎Inc. shares gained by almost 458.99% since the beginning of the year. However, the share price has ‎dropped to as low as -9.14% below its one year high. On 12/16/20, the company shares recorded ‎‎$24.30, the highest single-day price it has got to in the last 52-weeks and a 52-week low was seen on ‎‎03/13/20, the same year at $3.78. The company’s shares have inclined by 383.15% in the past year. The ‎‎50-day SMA achieved is $15.38 while the 200-day SMA is $9.40. Volume dropped to 0.25 million from ‎‎0.64 million in the previous session.‎‎

OCUL Stock Support And Resistance Levels

On the 24-hour scale, the immediate backing is ‎perceived around 21.63 level, and in case of violation of this particular level, it will cause more drop to ‎‎21.17 level. On the upper level, 22.99 is still the key resistance. The stock may increase to the ‎subsequent resistance at 22.54. The Relative Strength Index (RSI) pinned on the 14-day chart is 71.46, ‎implying a overbought technical stance while the MACD stands at 0.91, meaning price will decrease in ‎the next trading period. Percent R indicator moved to 35.35%, implying low price movement. ‎Stochastic %K at 65.93% suggest selling the stock.‎‎

What is the short interest in Ocular Therapeutix Inc.?

Short interest in the Ocular ‎Therapeutix Inc. stock has surged, increasing by 0.8 million shares to total 5.0 million shares on Dec 14, ‎‎2020. The interest had seen shares on Nov 12, 2020 stand at 5.8 million, data from Yahoo Finance ‎shows. The decrease of -16.0% suggests the stock saw some decreased bullish sentiment. The stock’s ‎days to cover (short ratio) moved to while the shorted shares account for just 7.84% of the overall ‎float for the stock.‎‎

Ocular Therapeutix Inc.’s Biggest Shareholders: Who Owns Ocular Therapeutix Inc. ‎‎[OCUL]?

Filings by Opaleye Management, Inc. showed that the firm now holds a total of ‎‎5,984,200 shares or roughly 8.38% of the outstanding OCUL shares. This means their shares have ‎reduced by 0 from the 5,984,200 the investor reportedly held in its prior 13-F filing. With the conclusion ‎of the sale, Summer Road LLC updated stake is worth $98,322,420. Details in the latest 13F filings reveal ‎that BlackRock Fund Advisors acquired their 13.54% stake valued at $65,054,745 while The Vanguard ‎Group, Inc. cut theirs at $49,557,498. During the last quarter, BlackRock Fund Advisors raised 443,326 of ‎its shares in Ocular Therapeutix Inc. while The Vanguard Group, Inc. sold -40,055 shares. The RA Capital ‎Management LP’s holdings currently number 2,727,272 shares at $60218165.76. According to the firm’s ‎last 13F report, Deltec Asset Management LLC shares in the company at filing stood at 2,472,067 ‎shares, roughly $43,261,173.‎‎

OCUL Earnings Forecast For The Current Quarter

Ocular Therapeutix Inc. [OCUL] is expected ‎to report strong earnings results for the quarter ending on Dec 2020. Consensus estimates give the ‎company expected revenues of $13.9M and an earnings per share of -$0.11 for Dec 2020. Looking ‎further ahead, the company is expected to report revenue of $10.19M at an EPS of -$0.17 for Mar ‎‎2021. The estimates represent upside of 137.20% and 58.70% in the company’s revenue and earnings ‎per share, respectively, on a year-on-year basis.‎‎

Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 

OCUL Earnings Estimates For The Current ‎Year

For the financial year, Ocular Therapeutix Inc. [NASDAQ:OCUL] is expected to bring in ‎revenue of $26.97M. The returns are nearly $22.74 million higher than the company’s actual revenue ‎recorded in the fiscal year 2019. In terms of EPS for the 2020, estimate put it at -1.19, higher than that ‎of FY19 by $0.72. Estimates put this year’s earnings growth at 37.70%, 49.60% for the next. As for sales, ‎forecasts are for an increase of 538.00% in the current fiscal year and a further 137.20% over the ‎following year.‎


Please enter your comment!
Please enter your name here